Eef Schimmelpennink, Lenz Therapeutics CEO
November 15, 2023 07:44 AM ESTUpdated 08:38 AM
Deals

Graphite Bio hands Nas­daq spot to pres­by­opia biotech Lenz Ther­a­peu­tics as PhI­II read­outs loom

Kyle LaHucik

Senior Reporter

Nine months af­ter throw­ing in the tow­el on its gene edit­ing pro­gram for sick­le cell dis­ease, Graphite Bio said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times